Colorectal Cancer News

Substitute Drug Fills Gap Left By Leucovorin Shortage

At the end of April, the FDA approved a substitute for leucovorin, a much-anticipated release during the ongoing shortage of the chemotherapy antidote. Fusilev, manufactured by Spectrum Pharmaceuticals, is a “ready-to-use” formulation of levoleucovorin for injection. The drug is used to treat the side effects of chemotherapy in patients with advanced colon cancer.

References:
FDA Current Drug Shortages

FDA Approves FUSILEV® for Use in Patients with Colorectal Cancer. Press Release. 2011 April 29.

Return